KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Jazz Pharmaceuticals (JAZZ) Long-Term Deferred Tax: 2012-2025

Historic Long-Term Deferred Tax for Jazz Pharmaceuticals (JAZZ) over the last 13 years, with Sep 2025 value amounting to $846.2 million.

  • Jazz Pharmaceuticals' Long-Term Deferred Tax rose 45.09% to $846.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $846.2 million, marking a year-over-year increase of 45.09%. This contributed to the annual value of $560.2 million for FY2024, which is 17.25% up from last year.
  • Latest data reveals that Jazz Pharmaceuticals reported Long-Term Deferred Tax of $846.2 million as of Q3 2025, which was up 40.35% from $602.9 million recorded in Q2 2025.
  • Jazz Pharmaceuticals' Long-Term Deferred Tax's 5-year high stood at $846.2 million during Q3 2025, with a 5-year trough of $258.5 million in Q1 2021.
  • Its 3-year average for Long-Term Deferred Tax is $544.7 million, with a median of $545.2 million in 2024.
  • Data for Jazz Pharmaceuticals' Long-Term Deferred Tax shows a peak YoY skyrocketed of 47.43% (in 2023) over the last 5 years.
  • Quarterly analysis of 5 years shows Jazz Pharmaceuticals' Long-Term Deferred Tax stood at $311.1 million in 2021, then climbed by 20.94% to $376.2 million in 2022, then climbed by 27.00% to $477.8 million in 2023, then rose by 17.25% to $560.2 million in 2024, then spiked by 45.09% to $846.2 million in 2025.
  • Its Long-Term Deferred Tax stands at $846.2 million for Q3 2025, versus $602.9 million for Q2 2025 and $575.1 million for Q1 2025.